Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis

Palframan, Roger; Airey, Michael; Moore, A. R.; Vugler, Alex; Nesbitt, Andrew

doi:10.1016/j.jim.2009.06.009

Cited by 116 publications

(60 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В ча-стности, R. Palframan и соавт. [32] показали, что концен-трация ЦЗП в очагах воспаления у мышей была выше, чем уровни ИНФ и АДА. Кроме того, ЦЗП дольше задер-живался в очаге, чем другие два препарата.…”

Section: Discussionunclassified

“…Кроме того, ЦЗП дольше задер-живался в очаге, чем другие два препарата. Данные свой-ства, наиболее вероятно, обусловлены пэгилированной структурой молекулы и отсутствием Fc-фрагмента [30,32] и могут являться преимуществами при лечении рев-матических заболеваний с очагами хронического воспа-ления, в частности, артериита Такаясу. В настоящее время ЦЗП (симзия) зарегистрирован для лечения ревматоидного артрита, псориатического арт-рита, анкилозирующего спондилита, а также болезни Кро-на.…”

Section: Discussionunclassified

See 1 more Smart Citation

Certolizumab Pegol in the Treatment of Takayasu Arteritis: The First Experience and Prospects

Novikov¹,

Smitienko²,

Соколова³

et al. 2018

rsp

View full text Add to dashboard Cite

Certolizumab pegol (CZP) is the only pegylated biological agent (BA) that does not contain an Fc fragment, which minimizes its transplacental transfer. Takayasu arteritis mostly occurs in reproductive-aged women.Objective: to evaluate the efficacy and safety of CZP used to treat standard immunosuppressive therapy-resistant Takayasu arteritis.Subjects and methods. The retrospective study enrolled 6 female patients aged 18 to 35 years with Takayasu arteritis who received CZP. The median disease duration before BA usage was 66 months (24 to 204 months). The median duration of immunosuppressive therapy prior to CZP treatment was 92 months (14 to 132 months). All the female patients had taken glucocorticoids and methotrexate before and during CZP therapy. Only four patients had received two to five immunosuppressive drugs at different times prior to BA administration. Three patients had previously used other BAs. The disease activity was determined by the National Institute of Health (NIH) criteria. The Indian Takayasu Clinical Activity Score (ITAS2010) was used. The disease activity was recorded in all the patients prior to CZP therapy.Results and discussion. The median duration of CZP treatment was 17 months (6 to 24 months). The median erythrocyte sedimentation rate after CZP usage decreased from 22.5 to 10.5 mm/h; the median C-reactive protein level dropped from 7.8 to 0.39 mg/dl (p<0.05), the median daily dose of prednisolone was reduced from 20 to 8.75 mg (p<0.05). All the patients achieved complete remission an average of 4 months after starting CZP therapy. Three patients were still in remission after 12–24 months. One relapse of the disease was recorded following 24 months. ITAS2010 reduced from 1–4 to 0 in five patients and to 2 in one patient with recurrence. There was a good tolerance in five female patients. The adverse events were herpes labialis in two cases, community-acquired pneumonia in one case, and postoperative abscess in one case too.Conclusion. CZP in Takayasu arteritis was shown to be an effective drug for remission induction and maintenance. The presented results of the first experience in treating this disease with CZP are indicative of its promising further investigation as a steroid-sparing drug in patients with refractory vasculitis. One of the important advantages of CZP is its supposed high safety throughout pregnancy.

show abstract

Section: Discussionunclassified

Certolizumab Pegol in the Treatment of Takayasu Arteritis: The First Experience and Prospects

Novikov¹,

Smitienko²,

Соколова³

et al. 2018

rsp

View full text Add to dashboard Cite

show abstract

“…Pegilasyonun mast hücrelerinde non-immün degranülasyonu da azaltt›¤› ve bunun da enjeksiyon yeri reaksiyonlar›n›n nadir olmas›n› aç›klayabilece¤i düflünülmektedir. [4,[20][21][22] Bir anti-TNF ajan›n TNF molekülüne monovalan veya bivalan ba¤lanmas›n›n bir önemi var m›d›r?…”

Section: Raedunclassified

Biological treatments

Gülbezer¹,

Keser²

2017

RAED Derg

View full text Add to dashboard Cite

“…Tumor biopsy evaluation with fine‐needle aspirations or tissue dissections is confounded by intracellular and nonspecific staining, and is limited by low quantitative capability of immunohistochemistry (IHC). Alternative strategies, at least in animal studies, include performing surrogate RO on encapsulated cells implanted subcutaneously 62, 63 or direct bioluminescent tissue imaging using intravenous injected fluorescence‐labeled, receptor‐specific antibodies in live animals 64, 65. In addition, the most plausible route to tissue‐based RO assays may be based on advances in the coupling of immunocytochemical methods with high‐resolution laser ablation linked mass cytometry, such as CyTOF mass cytometry imaging 66.…”

Section: Future Perspectivesmentioning

confidence: 99%

Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development

Liang¹,

Schwickart²,

Schneider³

et al. 2015

Cytometry Part B Clinical

View full text Add to dashboard Cite

Receptor occupancy (RO) assays are designed to quantify the binding of therapeutics to their targets on the cell surface and are frequently used to generate pharmacodynamic (PD) biomarker data in nonclinical and clinical studies of biopharmaceuticals. When combined with the pharmacokinetic (PK) profile, RO data can establish PKPD relationships, which are crucial for informing dose decisions. RO is commonly measured by flow cytometry on fresh blood specimens and is subject to numerous technical and logistical challenges. To ensure that reliable and high quality results are generated from RO assays, careful assay design, key reagent characterization, data normalization/reporting, and thorough planning for implementation are of critical importance during development. In this article, the authors share their experiences and perspectives in these areas and discuss challenges and potential solutions when developing and implementing a flow cytometry‐based RO method in support of biopharmaceutical drug development. © 2015 The Authors Cytometry Part B: Clinical Cytometry Published by Wiley Periodicals, Inc.

show abstract

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis

Cited by 116 publications

References 16 publications

Certolizumab Pegol in the Treatment of Takayasu Arteritis: The First Experience and Prospects

Certolizumab Pegol in the Treatment of Takayasu Arteritis: The First Experience and Prospects

Biological treatments

Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development

Contact Info

Product

Resources

About